Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

NCT01029886 · Completed

Last updated 2026-05-28

This clinical trial compared the safety and effects of two diabetes medications, exenatide once weekly and liraglutide, in adults with type 2 diabetes over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 912 people

Who can join Ages 18+ · all sexes

Timeline Started 2010-01 · est. completion 2011-04

Where 108 sites · Argentina, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Poland, Romania, Slovakia, South Africa, South Korea, Spain, Taiwan

What this study is testing ClinicalTrials.gov NCT01029886 ↗

Description as written by the study sponsor.

No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose.

Treatments tested

exenatide once weekly Drug

subcutaneous injection, 2mg, once weekly
liraglutide also known as Victoza Drug

subcutaneous injection, forced titration to 1.8mg, once daily

Main thing measured	Change in HbA1c From Baseline to Week 26
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	liraglutide, exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01029886 ↗